|
Match
|
Document |
Document Title |
|
|
6849254 |
HCV combination therapy
Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination...
|
|
|
6843988 |
Synferon
The present invention relates to a novel Synferon protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a synthetic interferon...
|
|
|
6838081 |
Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
The present invention provides methods for enhancing the development of APC from precursor cells by administering a combination of GM-CSF and IL-4. The precursor cells include: cells contained in...
|
|
|
6833256 |
Interferon tau mutants and methods for making them
The present invention is directed to the field of animal and human health, and more particularly to pharmacological uses of analogs or mutants of interferon-tau (IFN-τ) that differ from native...
|
|
|
6830744 |
Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type...
|
|
|
6824768 |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a...
|
|
|
6824769 |
Optimal compositions and methods thereof for treating HCV infections
The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor,...
|
|
|
6815422 |
Molecules with anti-inflammatory activity
Here is described the use of angiostatin or its fragments to prepare a drug active against pathologies where is beneficial to obtain the inhibition of the migration, activation and release of...
|
|
|
6787132 |
Combined chemo-immunotherapy with liposomal drugs and cytokines
A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The...
|
|
|
6773701 |
Expression enhancer for protein synthesis inhibitory genes
The objects of the present invention are to reveal a specific combination of human interferon-α subtypes that remarkably enhances the expression of protein synthesis inhibitory genes, and to...
|
|
|
6746670 |
Regulatory T cells; methods
Methods for increasing yields of Tr1 cells, useful, e.g., in transplantation contexts. Use of interferon and IL-15 are described.
|
|
|
6703225 |
Interferon-α
A novel human IFN-α subtype and its derivative having an unprecedentedly high specific activity, DNA encoding these proteins, an expression vector having said DNA, a transformant transformed with...
|
|
|
6685931 |
Treatment of hepatitis C virus infections with interleukin-10
The hepatoprotective effect of IL-10 is described, in particular, the use of interleukin-10 in the treatment of liver damage (e.g. fibrosis or cirrhosis) in a difficult-to-treat patient afflicted...
|
|
|
6667033 |
Therapeutic agent for chronic hepatitis B
The present invention provides an effective method for treating chronic hepatitis B. Specifically, the present invention provides a method for treating chronic hepatitis B wherein interferon (IFN)...
|
|
|
6663859 |
Compositions for enhancing the immune response
D-Ribose and methods for using D-Ribose are provided for enhancing the immune response in mammals. Those with a less than optimal immune response will benefit from oral or parenteral administration...
|
|
|
6635243 |
Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
The present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be...
|
|
|
6607914 |
Camello gene family and uses thereof
The present invention provides a purified and isolated nucleic acid encoding a camello protein. The present invention also provides a vector comprising nucleic acid encoding camello, a host cell...
|
|
|
6605273 |
Renal cell carcinoma treatment
Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of...
|
|
|
6569420 |
Human interferon-&egr : a type I interferon
The invention concerns a novel human interferon-ε, originally designated PRO655, and its variants and derivatives. The novel interferon is related to but distinct from members of the IFN-α family...
|
|
|
6524570 |
Polyethylene glycol modified interferon therapy
A method comprising administering a PEG 12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C,...
|
|
|
6506377 |
Interferon-alpha mediated upregulation of aquaporin expression
A method for enhancing the expression of aquaporin proteins by contacting aquaporin producing cells with interferon-α is described. The method enables treatment of patients afflicted with disease...
|
|
|
6489330 |
Use of penciclovir for the treatment of human herpes-virus-8
The present invention is directed to the use of a compound of Formula (A), or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the...
|
|
|
6472373 |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Methods for treating an antiviral treatment naive patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving administering a therapeutically effective amount of a...
|
|
|
6462017 |
Method of reducing side effects of chemotherapy in cancer patients
A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin α 1 in conjunction with the administration of a chemotherapy agent to the patient. As...
|
|
|
6461605 |
Continuous low-dose cytokine infusion therapy
A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished...
|
|
|
6444200 |
Composition and method for dermal and transdermal administration of a cytokine
A composition for transdermal administration of a cytokine is described. The composition includes a conjugate composed of a cytokine, such as an interferon, and at least one fatty acid moiety...
|
|
|
6436391 |
Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
The use of IFN-α subtypes as vaccine adjuvants is disclosed, together with vaccine compositions comprising them. Methods of vaccinating a subject comprising co-administration of IFN-α subtypes...
|
|
|
6433144 |
Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
This invention relates to methods for isolating highly purified mixtures of natural Type I interferon from white blood cells. The invention also relates to highly-purified mixtures of Type I...
|
|
|
6417237 |
Macromolecular drug complexes and compositions containing the same
Macromolecular drug complexes containing a drug, like human growth hormone, and a polymer having a plurality of acid moieties, like carboxyl moieties or phosphonic acid moieties, and compositions...
|
|
|
6410697 |
Process for purifying human leukocyte interferon
Disclosed is purified human leukocyte interferon, including human leukocyte interferon obtained from Namalva cells (“Namalva interferon”) which, for the first time, is shown to contain a...
|
|
|
6407068 |
Method of treating humans with diseases characterized by high secretion of cytokines from macrophage cells
A method of treating an individual who is suffering from human immunodeficiency virus infection is disclosed. Methods of treating a human suffering from a disease characterized by high secretion of...
|
|
|
6403095 |
Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6399070 |
Methods and compositions for eliciting an immune response with hsp90-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6399654 |
Biflavanoids and derivatives thereof as antiviral agents
Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are...
|
|
|
6387365 |
Combination therapy for chronic hepatitis C infection
There is disclosed a method for treating chronic hepatitis C infection in patients in need of such treating comprising administering an amount of alpha interferon in association with an amount of...
|
|
|
6383494 |
Methods and composition for eliciting an immune response with gp96-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6375946 |
Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
A method for providing activated natural killer (NK) cells comprising the steps of administering to a population of cells which includes lymphocytes and monocytes, an effective amount of an NK cell...
|
|
|
6372218 |
Interferon dosage form and method therefor
Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of...
|
|
|
6372207 |
IFNAR2/IFN complex
The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon α/β receptor (IFNAR)....
|
|
|
6361769 |
Stimulation of host defense mechanisms against viral challenges
A method for stimulating host defense mechanisms in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon...
|
|
|
6350443 |
Method of treatment for feline leukemia virus infections
A method of treatment for feline leukemia virus infections by continuously administering a feline interferon preparation containing a feline interferon as a main component daily to a cat is...
|
|
|
6346243 |
Inhibition of transplant rejection by type one interferon
The present invention provides a method of using a convenient, oral administered and non-toxic immunomodulating agent to suppress transplant rejection. Such agent is a type one interferon.
|
|
|
6319691 |
Fusion proteins comprising IFN-alpha2b and TM-alpha1
A fusion protein which comprises human IFN-alpha2b and human TM-alpha1. Such fusion proteins have enhanced biological activity and are useful for the treatment of viral, neoplastic and...
|
|
|
6300474 |
Modified interferons
A new class of polypeptides is disclosed, along with a method for identifying and producing such polypeptides, having the characteristic of being unique to diseased states, particularly tumors and...
|
|
|
6294540 |
Carbocyclic nucleoside hemisulfate and its use in treating viral infections
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2
-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
|
|
|
6277830 |
5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
5'-Amino acid esters of ribavirin represented by formula I: ##STR1## wherein R is CH 3 CH(NH 2 )--CO--, CH 3 CH 2 (CH 3 )CHCH(NH 2 )--CO--or H 2 N(CH 2 ) 4 CH(NH 2 )--CO--; preferably R is...
|
|
|
6250469 |
Formulations for protection of peg-interferon alpha conjugates
The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect...
|
|
|
6239137 |
Salts of aminoimidazole carboxamide and 5 amino or substituted amino 1,2,3-triazole, induce apoptosis, inhibit DNA synthesis and control cyclooxygenase activity
Compositions and methods are described for the induction of apoptosis inhibition of DNA synthesis, and/or inhibiting COX-2 activity using an effective amount of salts of aminoimidazole carboxamide,...
|
|
|
6207145 |
Therapeutic applications of high dose interferon
Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal with a stimulating amount of the interferon which exceeds parenterally...
|
|
|
6204022 |
Low-toxicity human interferon-alpha analogs
The invention describes a method of reducing the cytotoxicity of interferon-alpha by making defined amino acid substitutions in the N-terminal portion of the polypeptide sequence. Also described...
|